LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• FitzmauriceCAllenCGlobal Burden of Disease Cancer CollaborationGlobal, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease StudyJAMA Oncol20173452454827918777
   PubMed Web of Science ®Google Scholar
• van CutsemESagaertXTopalBHaustermansKPrenenHGastric cancerLancet2016388100602654266427156933
   PubMed Web of Science ®Google Scholar
• KongFQiYLiuHSurgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosisClin Transl Oncol2015171191792426088414
   PubMed Web of Science ®Google Scholar
• CidónEUGastric cancer and the search for a good prognostic classification: a challengeClin Exp Gastroenterol2010311311621694854
   PubMedGoogle Scholar
• Cruz-ReyesCGamboa-DominguezAHER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotypeInt J Surg Pathol201321324024623564704
   PubMed Web of Science ®Google Scholar
• ZhangYWuSNovel therapy for advanced gastric cancerWorld J Gastrointest Oncol201571126327026600926
   PubMed Web of Science ®Google Scholar
• DigkliaAWagnerADAdvanced gastric cancer: Current treatment landscape and future perspectivesWorld J Gastroenterol20162282403241426937129
   PubMed Web of Science ®Google Scholar
• HartgrinkHHJansenEPvan GriekenNCvan de VeldeCJGastric cancerLancet2009374968847749019625077
   PubMed Web of Science ®Google Scholar
• JomrichGSchoppmannSFTargeted therapy in gastric cancerEur Surg201648527828427795701
   PubMedGoogle Scholar
• BangYJVan CutsemEToGA Trial InvestigatorsTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• LiJQinSXuJRandomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastro-esophageal JunctionJ Clin Oncol201634131448145426884585
   PubMed Web of Science ®Google Scholar
• LordickFKangYKArbeitsgemeinschaft Internistische Onkologie and EXPAND InvestigatorsCapecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialLancet Oncol201314649049923594786
   PubMed Web of Science ®Google Scholar
• OhtsuAShahMAvan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III studyJ Clin Oncol201129303968397621844504
   PubMed Web of Science ®Google Scholar
• OhtsuAAjaniJABaiYXEverolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyJ Clin Oncol201331313935394324043745
   PubMed Web of Science ®Google Scholar
• OueNHamaiYMitaniYGene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expressionCancer Res20046472397240515059891
   PubMed Web of Science ®Google Scholar
• KissHKedraDYangYA novel gene containing LIM domains (LIMD1) is located within the common eliminated region 1 (C3CER1) in 3p21.3Hum Genet1999105655255910647888
   PubMed Web of Science ®Google Scholar
• BachIThe LIM domain: regulation by associationMech Dev2000911–251710704826
   PubMed Web of Science ®Google Scholar
• ZabarovskyERLermanMIMinnaJDTumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancersOncogene200221456915693512362274
   PubMed Web of Science ®Google Scholar
• YangQYoshimuraGMoriISakuraiTKakudoKChromosome 3p and breast cancerJ Hum Genet200247945345912202982
   PubMed Web of Science ®Google Scholar
• SenchenkoVLiuJBragaEDeletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomasOncogene200322192984299212771950
   PubMed Web of Science ®Google Scholar
• ReznikoffCABelairCDYeagerTRA molecular genetic model of human bladder cancer pathogenesisSemin Oncol19962355715848893868
   PubMed Web of Science ®Google Scholar
• VelickovicMDelahuntBStörkelSGrebemSKVHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significanceCancer Res200161124815481911406557
   PubMed Web of Science ®Google Scholar
• FengYLongmoreGDThe LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complexMol Cell Biol200525104010402215870274
   PubMed Web of Science ®Google Scholar
• JamesVZhangYFoxlerDELIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-mediated gene silencingProc Natl Acad Sci U S A201010728124991250420616046
   PubMed Web of Science ®Google Scholar
• LangerEMFengYZhaoyuanHRauscherFJKrollKLLongmoreGDAjuba LIM proteins are snail/slug corepressors required for neural crest development in XenopusDev Cell200814342443618331720
   PubMed Web of Science ®Google Scholar
• SharpTVMunozFBourbouliaDLIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcriptionProc Natl Acad Sci U S A200410147165311653615542589
   PubMed Web of Science ®Google Scholar
• das ThakurMFengYJagannathanRSeppaMJSkeathJBLongmoreGDAjuba LIM proteins are negative regulators of the Hippo signaling pathwayCurr Biol201020765766220303269
   PubMed Web of Science ®Google Scholar
• SharpTVAl-AttarAFoxlerDEThe chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer developmentProc Natl Acad Sci U S A200810550199321993719060205
   PubMed Web of Science ®Google Scholar
• SpendloveIAl-AttarAWatherstoneODifferential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survivalInt J Cancer2008123102247225318712738
   PubMed Web of Science ®Google Scholar
• HouXLiTRenZLiuYNovel BRCA2-Interacting Protein, LIMD1, Is Essential for the Centrosome Localization of BRCA2 in Esophageal Cancer CellOncol Res201624424725327656835
   PubMed Web of Science ®Google Scholar
• PanDThe hippo signaling pathway in development and cancerDev Cell201019449150520951342
   PubMed Web of Science ®Google Scholar
• YuFXZhaoBPanupinthuNRegulation of the Hippo-YAP pathway by G-protein-coupled receptor signalingCell2012150478079122863277
   PubMed Web of Science ®Google Scholar
• BeyerTAWeissAKhomchukYSwitch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cellsCell Rep2013561611162424332857
   PubMed Web of Science ®Google Scholar
• SlatteryMVoutevRMaLNègreNWhiteKPMannRSDivergent transcriptional regulatory logic at the intersection of tissue growth and developmental patterningPLoS Genet201399e100375324039600
   PubMed Web of Science ®Google Scholar
• KangWTongJHChanAWYes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosisClin Cancer Res20111782130213921346147
   PubMed Web of Science ®Google Scholar
• ZhouZZhuJSGaoCPsiRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID miceOncol Lett20161142806281427073556
   PubMed Web of Science ®Google Scholar
• SongMCheongJHKimHNohSHKimHNuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancerAnticancer Res20123293827383422993325
   PubMed Web of Science ®Google Scholar
• daCLXinYZhaoJLuoXDSignificance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesionsWorld J Gastroenterol200915324055406119705503
   PubMed Web of Science ®Google Scholar
• SzászAMLánczkyANagyÁCross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patientsOncotarget2016731493224933327384994
   PubMedGoogle Scholar
• Díez-VillanuevaAMallonaIPeinadoMAWanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancerEpigenetics Chromatin201582226113876
   PubMed Web of Science ®Google Scholar
• GhoshSGhoshAMaitiGPAlterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosisInt J Cancer2008123112594260418792900
   PubMed Web of Science ®Google Scholar
• HugginsCJAndrulisILCell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancersCancer Lett20082671556618439753
   PubMed Web of Science ®Google Scholar
• IbarCKirichenkoEKeepersBEnnersEFleischKIrvineKDTension-dependent regulation of mammalian Hippo signaling through LIMD1J Cell Sci20181315jcs21470029440237
   PubMed Web of Science ®Google Scholar
• PetursdottirTEThorsteinsdottirUJonassonJGInterstitial deletions including chromosome 3 common eliminated region 1 (C3CER1) prevail in human solid tumors from 10 different tissuesGenes Chromosomes Cancer200441323224215334546
   PubMed Web of Science ®Google Scholar